Digital technology could drastically improve diabetic retinopathy screening

Article

Digital imaging technology, used during primary care visits, can significantly improve screening rates for diabetic retinopathy, according to a report published in the March issue of Diabetes Care.

Digital imaging technology, used during primary care visits, can significantly improve screening rates for diabetic retinopathy, according to a report published in the March issue of Diabetes Care.

Cathy Taylor and colleagues from the Vanderbilt University, Nashville, USA conducted a retrospective cohort study of all diabetic patients aged 18 years (n=495), seen at Vine Hill Community Clinic between the 1st September 2003 and the 31st August 2004. Each subject was offered ophthalmology referral or digital screening. Those who chose the referral received the next available (within three months) appointment at the Vanderbilt Eye Clinic; patients choosing digital screening were screened during the visit.

Of the 293 patients screened, 92 (31.4%) were screened at referral, and 201 (68.6%) were digitally screened. Among the 201 digitally screened patients, 104 (51.7%) tested negative and were advised to return for re-screening in one year. A total 75 (37.3%) screened positive and were referred for a non-urgent follow-up while 22 (11.0%) screened positive for sight-threatening eye disease and were urgently referred for ophthalmological follow-up. Digital imaging technical failure rate was 0.5%.

It was concluded that digital screening technology could dramatically improve screening rates for diabetic retinopathy.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.